JP6657193B2 - 薬物送達および前眼部保護のための眼用製剤 - Google Patents

薬物送達および前眼部保護のための眼用製剤 Download PDF

Info

Publication number
JP6657193B2
JP6657193B2 JP2017514892A JP2017514892A JP6657193B2 JP 6657193 B2 JP6657193 B2 JP 6657193B2 JP 2017514892 A JP2017514892 A JP 2017514892A JP 2017514892 A JP2017514892 A JP 2017514892A JP 6657193 B2 JP6657193 B2 JP 6657193B2
Authority
JP
Japan
Prior art keywords
months
compound
formulation
active
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017514892A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017527600A (ja
JP2017527600A5 (enExample
Inventor
ビンガマン，デビッド・ピー
チェイニー，ポール・ジー
ワックス，マーティン・ビー
Original Assignee
パンオプティカ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パンオプティカ，インコーポレイテッド filed Critical パンオプティカ，インコーポレイテッド
Publication of JP2017527600A publication Critical patent/JP2017527600A/ja
Publication of JP2017527600A5 publication Critical patent/JP2017527600A5/ja
Priority to JP2020016790A priority Critical patent/JP6890692B2/ja
Application granted granted Critical
Publication of JP6657193B2 publication Critical patent/JP6657193B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017514892A 2014-09-17 2015-09-17 薬物送達および前眼部保護のための眼用製剤 Active JP6657193B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020016790A JP6890692B2 (ja) 2014-09-17 2020-02-04 薬物送達および前眼部保護のための眼用製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051794P 2014-09-17 2014-09-17
US62/051,794 2014-09-17
PCT/US2015/050818 WO2016044671A1 (en) 2014-09-17 2015-09-17 Ocular formulations for drug-delivery and protection of the anterior segment of the eye

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020016790A Division JP6890692B2 (ja) 2014-09-17 2020-02-04 薬物送達および前眼部保護のための眼用製剤

Publications (3)

Publication Number Publication Date
JP2017527600A JP2017527600A (ja) 2017-09-21
JP2017527600A5 JP2017527600A5 (enExample) 2018-10-18
JP6657193B2 true JP6657193B2 (ja) 2020-03-04

Family

ID=55453708

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017514892A Active JP6657193B2 (ja) 2014-09-17 2015-09-17 薬物送達および前眼部保護のための眼用製剤
JP2020016790A Active JP6890692B2 (ja) 2014-09-17 2020-02-04 薬物送達および前眼部保護のための眼用製剤
JP2021086698A Active JP7176042B2 (ja) 2014-09-17 2021-05-24 薬物送達および前眼部保護のための眼用製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020016790A Active JP6890692B2 (ja) 2014-09-17 2020-02-04 薬物送達および前眼部保護のための眼用製剤
JP2021086698A Active JP7176042B2 (ja) 2014-09-17 2021-05-24 薬物送達および前眼部保護のための眼用製剤

Country Status (19)

Country Link
US (6) US9814702B2 (enExample)
EP (2) EP3878449B1 (enExample)
JP (3) JP6657193B2 (enExample)
KR (2) KR102450020B1 (enExample)
CN (2) CN113209000B (enExample)
AU (2) AU2015317531B2 (enExample)
CA (1) CA2958315A1 (enExample)
DK (1) DK3193867T3 (enExample)
ES (2) ES3010497T3 (enExample)
HU (1) HUE053852T2 (enExample)
IL (2) IL282504B (enExample)
MA (1) MA56220A (enExample)
MX (2) MX383792B (enExample)
NZ (1) NZ767710A (enExample)
PL (1) PL3193867T3 (enExample)
PT (1) PT3193867T (enExample)
RU (2) RU2704810C2 (enExample)
WO (1) WO2016044671A1 (enExample)
ZA (1) ZA201701303B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021121624A (ja) * 2014-09-17 2021-08-26 パンオプティカ，インコーポレイテッド 薬物送達および前眼部保護のための眼用製剤

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201907400YA (en) * 2018-07-18 2020-02-27 Univ Wenzhou Medical Method for treating myopia and application in preparation of medicament
EP3870204A4 (en) * 2018-10-24 2022-12-21 Allysta Pharmaceuticals, Inc. Adiponectin peptidomimetics formulations
JP2022131565A (ja) * 2021-02-26 2022-09-07 ロート製薬株式会社 水性医薬組成物
KR102633321B1 (ko) * 2021-05-11 2024-02-05 연세대학교 산학협력단 노인성 황반변성의 예방 또는 치료를 위한 약학 조성물
CN115521901B (zh) * 2022-10-12 2023-09-05 中国医学科学院医学生物学研究所 永生化树鼩视网膜微血管内皮细胞株及其构建方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053806A1 (en) * 1997-05-26 1998-12-03 New Vision Co., Ltd. Medicinal compositions for topical administration containing vitamin d and vitamin k
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
YU36403A (sh) * 2000-11-28 2006-08-17 Pfizer Products Inc. Soli izotiazol-4-karboksamida kao anti-hiperproliferacioni agensi
US20060127505A1 (en) * 2002-01-16 2006-06-15 David Haines Anti-inflammatory formulations
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
CN1946352A (zh) * 2004-04-09 2007-04-11 狄科特康坦特公司 递送药物至眼以治疗后段疾病的方法和物品
US20060134226A1 (en) * 2004-11-16 2006-06-22 Todd Leonard Compositions useful to treat ocular neovascular diseases and macular degeneration
WO2007041499A2 (en) * 2005-09-30 2007-04-12 Lipoprotein Technologies, Inc. Cox inhibitor and nicotinic acid compositions and methods
WO2009129859A1 (en) * 2008-04-24 2009-10-29 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Compositions and methods for maintaining, strengthening, improving, or promoting eye health
AU2010221438C1 (en) * 2009-03-03 2015-01-29 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
RU2012105453A (ru) 2009-08-11 2013-09-20 Аллерган, Инк. Изотиозолы для лечения состояний глаз
EP2482677A1 (en) * 2009-09-30 2012-08-08 The Regents of The University of California Cofactors and methods for use for individuals
WO2012012404A1 (en) 2010-07-19 2012-01-26 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
JP5956992B2 (ja) * 2010-08-17 2016-07-27 オーエイチアール・ファーマシューティカル・インコーポレイテッドＯｈｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌ，Ｉｎｃ． スクアラミンの眼用製剤
EP2444063A1 (en) * 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
WO2012162627A1 (en) * 2011-05-26 2012-11-29 The General Hospital Corporation Treatment of angiogenic- or vascular-associated diseases
JP6363506B2 (ja) * 2011-11-15 2018-07-25 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ シクロスポリンａ２型の懸濁剤
CA2865132A1 (en) * 2012-02-22 2013-08-29 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
SG11201507316UA (en) * 2013-03-14 2015-10-29 Panoptica Inc Ocular formulations for drug-delivery to the posterior segment of the eye
MA56220A (fr) * 2014-09-17 2022-04-20 Panoptica Inc Formulations oculaires permettant l'administration de médicament et la protection du segment antérieur de l'oeil

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021121624A (ja) * 2014-09-17 2021-08-26 パンオプティカ，インコーポレイテッド 薬物送達および前眼部保護のための眼用製剤
JP7176042B2 (ja) 2014-09-17 2022-11-21 パンオプティカ，インコーポレイテッド 薬物送達および前眼部保護のための眼用製剤

Also Published As

Publication number Publication date
PT3193867T (pt) 2021-03-09
RU2017112930A (ru) 2018-10-17
KR102450020B1 (ko) 2022-09-30
CA2958315A1 (en) 2016-03-24
EP3193867A1 (en) 2017-07-26
ES3010497T3 (en) 2025-04-03
IL282504B (en) 2022-08-01
EP3193867A4 (en) 2018-05-02
MX2017003436A (es) 2017-07-28
MX383792B (es) 2025-03-14
US20160206599A1 (en) 2016-07-21
BR112017005523A2 (pt) 2017-12-05
CN113209000A (zh) 2021-08-06
MA56220A (fr) 2022-04-20
IL282504A (en) 2021-06-30
JP2021121624A (ja) 2021-08-26
ES2863601T3 (es) 2021-10-11
HUE053852T2 (hu) 2021-07-28
US20210275501A1 (en) 2021-09-09
DK3193867T3 (da) 2021-04-06
US20190314343A1 (en) 2019-10-17
PL3193867T3 (pl) 2021-07-12
RU2017112930A3 (enExample) 2019-04-11
KR20220137157A (ko) 2022-10-11
EP3878449A1 (en) 2021-09-15
US9814702B2 (en) 2017-11-14
AU2015317531A1 (en) 2017-03-09
AU2021200997B2 (en) 2023-02-02
JP7176042B2 (ja) 2022-11-21
JP2020079274A (ja) 2020-05-28
MX2021006070A (es) 2021-07-06
WO2016044671A1 (en) 2016-03-24
JP2017527600A (ja) 2017-09-21
AU2015317531B2 (en) 2020-11-19
CN113209000B (zh) 2025-05-13
JP6890692B2 (ja) 2021-06-18
AU2021200997A1 (en) 2021-03-11
US10183014B2 (en) 2019-01-22
US20160074371A1 (en) 2016-03-17
IL251019B (en) 2021-05-31
US20240277674A1 (en) 2024-08-22
IL251019A0 (en) 2017-04-30
RU2704810C2 (ru) 2019-10-31
ZA201701303B (en) 2021-07-28
EP3193867B1 (en) 2021-01-20
US9623011B2 (en) 2017-04-18
NZ729142A (en) 2023-08-25
RU2768652C1 (ru) 2022-03-24
KR102555091B1 (ko) 2023-07-13
CN106999476A (zh) 2017-08-01
US20180078531A1 (en) 2018-03-22
NZ767710A (en) 2023-09-29
CN106999476B (zh) 2021-05-04
EP3878449B1 (en) 2024-10-30
KR20170058976A (ko) 2017-05-29

Similar Documents

Publication Publication Date Title
JP6965308B2 (ja) 後眼部へ薬物を送達するための眼用製剤
JP7176042B2 (ja) 薬物送達および前眼部保護のための眼用製剤
HK40059709A (en) Ocular formulations for drug-delivery and protection of the anterior segment of the eye
HK40060903B (en) Ocular formulations for drug-delivery and protection of the anterior segment of the eye
HK40060903A (en) Ocular formulations for drug-delivery and protection of the anterior segment of the eye
HK1236824B (en) Ocular formulations for drug-delivery and protection of the anterior segment of the eye
HK1236824A1 (en) Ocular formulations for drug-delivery and protection of the anterior segment of the eye
BR112017005523B1 (pt) Formulação de suspensão ocular tópica e uso da mesma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180904

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191024

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200205

R150 Certificate of patent or registration of utility model

Ref document number: 6657193

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250